Publications by authors named "P J van Diest"
Immune checkpoint inhibitor (ICI) treatment has proven successful for advanced melanoma, but is associated with potentially severe toxicity and high costs. Accurate biomarkers for response are lacking. The present work is the first to investigate the value of deep learning on CT imaging of metastatic lesions for predicting ICI treatment outcomes in advanced melanoma.
View Article and Find Full Text PDFArticle Synopsis
- Ductal carcinoma in-situ (DCIS) is a non-invasive breast cancer type that makes up about 25% of breast cancer cases, but it often leads to unnecessary aggressive treatment despite many cases never progressing to invasive cancer.
- A study analyzed 197 breast tissue samples to explore molecular changes in DCIS, using techniques like mRNA expression and DNA analysis to compare progressing versus non-progressing cases.
- The research found significant molecular differences among DCIS subtypes and between DCIS and invasive breast cancer, highlighting the complexity of DCIS and the need for more tailored approaches to assess risk and treatment.
: Pathological ultrastaging, an essential part of sentinel lymph node (SLN) mapping, involves serial sectioning and immunohistochemical (IHC) staining in order to reliably detect clinically relevant metastases. However, ultrastaging is labor-intensive, time-consuming, and costly. Deep learning algorithms offer a potential solution by assisting pathologists in efficiently assessing serial sections for metastases, reducing workload and costs while enhancing accuracy.
View Article and Find Full Text PDFMitotic count (MC) is the most common measure to assess tumor proliferation in breast cancer patients and is highly predictive of patient outcomes. It is, however, subject to inter- and intraobserver variation and reproducibility challenges that may hamper its clinical utility. In past studies, artificial intelligence (AI)-supported MC has been shown to correlate well with traditional MC on glass slides.
View Article and Find Full Text PDFPatients who present with breast cancer bone metastasis only have limited palliative treatment strategies and efficacious drug treatments are needed. In breast cancer patient data, high levels of the RNA helicase DDX3 are associated with poor overall survival and bone metastasis. Consequently, our objective was to target DDX3 in a mouse breast cancer bone metastasis model using a small molecule inhibitor of DDX3, RK-33.
View Article and Find Full Text PDF